Asahi Kasei agrees to acquire Bionova Scientific LLC
Asahi Kasei Medical concluded an agreement on April 14, 2022 (JST) through a U.S. subsidiary to wholly acquire Bionova Scientific, LLC, a provider of contract process development services and GMP-compliant contract manufacturing services to biopharmaceutical companies, especially those developing next-generation antibody based drugs.
Bionova Scientific’s process development capabilities are particularly highly regarded in the industry, and it has a rich track record regarding complex next-generation antibody drugs, which are typically challenging to manufacture. Its GMP manufacturing facility has state-of-the-art equipment including single-use bioreactors, suited to meet rising demand driven by the expansion of the antibody drug market and a steep increase in the number of biopharmaceuticals entering the clinical pipeline. Acquiring Bionova Scientific will enable Asahi Kasei Medical to add a biopharmaceutical CDMO (contract development and manufacturing organization) to its bioprocess business.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins